What is driving the PHARM.AS stock rally pre-market?

The rally is driven by heavy volume of **51.61M** shares and positioning ahead of a **12 Mar 2026** earnings release plus clinical and partnership updates. High relative volume suggests institutional flows and speculative trading.

How does Meyka AI rate PHARM.AS stock?

Meyka AI rates PHARM.AS with a score out of 100: **64.08 | Grade: B | Suggestion: HOLD**. The grade factors in benchmark comparison, sector performance, growth and analyst consensus.

What price targets and forecast exist for PHARM.AS stock?

Meyka AI's model projects **€1.93** in one year (+14.06%) and **€3.02** in three years (+78.67%). These are model-based projections and not guarantees.

What are the main risks for PHARM.AS stock traders?

Key risks include clinical trial setbacks, disappointing earnings, and valuation compression. Overbought technicals increase pullback risk during high-volume trading days.

EU Stocks

PRE MARKET: PHARM.AS Pharming EURONEXT €1.69 23 Jan 2026: +11.33%, 51.61M vol, momentum

ByDanny Kontos January 23, 2026January 23, 2026

PHARM.AS stock opened the pre-market session sharply higher at €1.69, up 11.33% on 51,612,443 shares traded as of this update. The move pushes price to the day high and year high, well above the 50-day average of €1.4566 and the 200-day average of €1.1407. Volume is more than three times the average, signalling unusually strong interest ahead of upcoming catalysts. We review what is driving the most active trading on EURONEXT and how valuation, technicals, and model forecasts map to near-term targets.